Published in Medical Devices and Surgical Technology Week, November 7th, 2004
Miravant also announced that the United States Adopted Name Council (USAN) has designated "rostaporfin" as the drug's unique generic name. USAN is the agency that assigns generic names to pharmaceuticals.
"We believe that PHOTREX is a powerful and distinctive brand name for SnET2 photodynamic therapy," said Gary S. Kledzik, Ph.D., Miravant's chairman and CEO. On Sep. 30, 2004, the U.S. Food and Drug Administration (FDA) issued an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week